Home > >

Direct treatment cost of patients with psoriatic arthritis disease covered by the social health insurance at the National Hospital of Dermatology and Venereology from 2021 to 2022

Code : SKPT_23_059
Publish date : 29/02/2024
Page : 29-36
Author : Nguyen Thi Mai Phuong
View : ( 1508 )

Others author (*)

Nguyen Thi Mai Phuong ₁ - Hanoi University of Public Health
Hua Thanh Thuy ₂ - Hanoi University of Public Health
Vuong Trong Hieu ₃ - Ha Noi University of Pharmacy
Do Thi Thu Hien ₄ - National Hospital of Dermatology and Venereology
Nguyen Van Thanh ₅ - National Hospital of Dermatology and Venereology
Pham Nu Hanh Van - Ha Noi University of Pharmacy

Objective: Estimate the direct medical costs of treating psoriatic arthritis (PsA), including in-patient and out-patient treatment costs.

Methods: The retrospective study follows a prevalence-based approach, collecting all patients with PsA undergoing treatment at the National Hospital of Dermatology and Venereology from July 1, 2021 to December 31, 2022. Data collected included demographic characteristics and costs covered by the social health insurance (SHI).

Results: Among the 74 patients included in the study, 64 patients received outpatient treatment, eight patients received both outpatient and inpatient treatment, and two patients received inpatient treatment only. The average monthly cost of outpatient treatment was 1.7 ± 2.2 million VND, with an average of 0.7 ± 0.3 outpatient visits per month. The average cost for an inpatient treatment session was 6.8 ± 6.2 million VND, with an average duration of 16.2 ± 20.9 days.

Conclusions: We have analyzed the economic burden of PsA from SHI perspective and shown medication costs accounted for the highest proportion of expenses in all cost categories.

DOI : https://doi.org/10.38148/JHDS.0801SKPT23-059
Topics : Quản lý hệ thống y tế
Type of article : Nghiên cứu gốc
Specialized : Chuyên Ngành Y

File download